ECSP099471A - Formas cristalinas de glyt1 - Google Patents

Formas cristalinas de glyt1

Info

Publication number
ECSP099471A
ECSP099471A EC2009009471A ECSP099471A ECSP099471A EC SP099471 A ECSP099471 A EC SP099471A EC 2009009471 A EC2009009471 A EC 2009009471A EC SP099471 A ECSP099471 A EC SP099471A EC SP099471 A ECSP099471 A EC SP099471A
Authority
EC
Ecuador
Prior art keywords
manufacture
glyt1
present
glass forms
trifluor
Prior art date
Application number
EC2009009471A
Other languages
English (en)
Inventor
Emmanuel Pinard
Olaf Grassmann
Franziska E Rohrer
Andre Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Kai Lindenstruth
Urs Schwitter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP099471A publication Critical patent/ECSP099471A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a cuatro formas cristalinas distintas y a una forma amorfa de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((S)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona y a su utilización para la fabricación de composiciones farmacéuticas.Los compuestos de la presente invención son idóneos para la fabricación de un medicamento destinado al tratamiento de psicosis, dolor, disfunción neurodegenerativa en memoria y apren-dizaje, esquizofrenia, demencia y otras enfermedades en las que están desequilibrados los procesos cognitivos, por ejemplo los trastornos con déficit de atención o la enfermedad de Alzheimer.
EC2009009471A 2006-12-28 2009-06-26 Formas cristalinas de glyt1 ECSP099471A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28

Publications (1)

Publication Number Publication Date
ECSP099471A true ECSP099471A (es) 2009-07-31

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009471A ECSP099471A (es) 2006-12-28 2009-06-26 Formas cristalinas de glyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (es)
EP (1) EP2114405B1 (es)
JP (1) JP4799666B2 (es)
KR (1) KR101130146B1 (es)
CN (1) CN101573114A (es)
AR (1) AR064545A1 (es)
AU (1) AU2007341356B2 (es)
BR (1) BRPI0720829B8 (es)
CA (1) CA2673667A1 (es)
CL (1) CL2007003830A1 (es)
CO (1) CO6190613A2 (es)
CR (1) CR10846A (es)
CY (1) CY1116350T1 (es)
DK (1) DK2114405T3 (es)
EC (1) ECSP099471A (es)
ES (1) ES2535040T3 (es)
HR (1) HRP20150573T1 (es)
HU (1) HUE025032T2 (es)
MA (1) MA31029B1 (es)
MX (1) MX2009006859A (es)
MY (1) MY188367A (es)
NO (1) NO342150B1 (es)
NZ (1) NZ577502A (es)
PE (1) PE20081556A1 (es)
PL (1) PL2114405T3 (es)
PT (1) PT2114405E (es)
RS (1) RS53910B1 (es)
RU (1) RU2463295C2 (es)
SI (1) SI2114405T1 (es)
TW (1) TWI388552B (es)
UA (1) UA100232C2 (es)
WO (1) WO2008080821A1 (es)
ZA (1) ZA200904423B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008080821A1 (en) 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1
WO2010099323A1 (en) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
WO2013174694A1 (en) * 2012-05-25 2013-11-28 Basf Se Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
WO2022241274A1 (en) * 2021-05-14 2022-11-17 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
MXPA06001665A (es) * 2003-08-11 2006-04-28 Hoffmann La Roche Piperazina con grupo fenilo sustituido -or y su uso como inhibidores del transportador de glicina 1 (glyt-1).
WO2008080821A1 (en) 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1

Also Published As

Publication number Publication date
PE20081556A1 (es) 2008-11-28
JP2010514725A (ja) 2010-05-06
US20100311971A1 (en) 2010-12-09
US20110295007A1 (en) 2011-12-01
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
TWI388552B (zh) 2013-03-11
CY1116350T1 (el) 2017-03-15
HUE025032T2 (en) 2016-02-29
KR20090094166A (ko) 2009-09-03
TW200833677A (en) 2008-08-16
BRPI0720829B1 (pt) 2020-04-07
BRPI0720829A2 (pt) 2014-02-25
ES2535040T3 (es) 2015-05-04
HRP20150573T1 (en) 2015-07-03
KR101130146B1 (ko) 2012-03-28
MY188367A (en) 2021-12-06
SI2114405T1 (sl) 2015-06-30
CR10846A (es) 2009-08-12
CN101573114A (zh) 2009-11-04
ZA200904423B (en) 2010-05-26
NO20092358L (no) 2009-06-22
PT2114405E (pt) 2015-06-02
MA31029B1 (fr) 2009-12-01
CA2673667A1 (en) 2008-07-10
CL2007003830A1 (es) 2008-07-11
BRPI0720829B8 (pt) 2021-05-25
US20120309969A1 (en) 2012-12-06
WO2008080821A1 (en) 2008-07-10
US20080214561A1 (en) 2008-09-04
RU2009124113A (ru) 2011-02-10
AU2007341356A1 (en) 2008-07-10
RS53910B1 (en) 2015-08-31
CO6190613A2 (es) 2010-08-19
US8039473B2 (en) 2011-10-18
NO342150B1 (no) 2018-04-03
DK2114405T3 (en) 2015-04-07
MX2009006859A (es) 2009-07-03
AR064545A1 (es) 2009-04-08
NZ577502A (en) 2012-02-24
EP2114405B1 (en) 2015-03-11
PL2114405T3 (pl) 2015-08-31
UA100232C2 (uk) 2012-12-10
RU2463295C2 (ru) 2012-10-10
US20130197225A1 (en) 2013-08-01
JP4799666B2 (ja) 2011-10-26

Similar Documents

Publication Publication Date Title
ECSP099471A (es) Formas cristalinas de glyt1
ECSP066358A (es) PIPERAZINA CON GRUPO FENIL OR-SUSTITUIDO Y SU USO COMO INHIBIDORES GlyT1
DOP2009000258A (es) Compuestos amino-heterociclicos
BRPI0414209B8 (pt) derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
CU20110106A7 (es) Nuevos compuestos 578
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
CO6362014A2 (es) Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso
UY32391A (es) Compuestos amino-heterocíclicos
ECSP10010506A (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A.
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
UY29451A1 (es) Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida
ECSP11010947A (es) Compuestos n- sulfonamido pirazolil policíclicos
EA201592278A1 (ru) Производные 4-амино-6-фенил-5,6-дигидроимидазо[1,5-a]пиразин-3(2h)-она в качестве ингибиторов бета-секретазы (bace)
NZ593279A (en) Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
BRPI0517549A (pt) novas propenonas cìclicas e acìclicas para o tratamento de distúrbios do snc
DE602007012272D1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
UY30612A1 (es) Derivados 5,7 disustituidos de la [1,3]tiazolo[4,5,d]pirimidin-2(3h)-ona, proceso de preparacion y aplicaciones
WO2007045060A8 (en) Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production
TH107358B (th) รูปแบบผลึก Glytl
TH77909A (th) พิเพอราซีนที่มีการแทนที่-OR สำหรับ GlyT1
UY31078A1 (es) Compuestos amino-heterociclicos
CR10431A (es) Sales y modificaciones del cristal de las mismas
TH77909B (th) พิเพอราซีนที่มีการแทนที่-OR สำหรับ GlyT1